Suppr超能文献

通过mRNA展示技术发现一种新型程序性死亡配体1(PD-L1)结合肽(一种PD-L1的肽配体)。

mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1).

作者信息

Kamalinia Golnaz, Engel Brian J, Srinivasamani Anupallavi, Grindel Brian J, Ong Justin N, Curran Michael A, Takahashi Terry T, Millward Steven W, Roberts Richard W

机构信息

Department of Chemistry, University of Southern California, Los Angeles, California 90089, United States.

Department of Cancer Systems Imaging, MD Anderson Cancer Center, Houston, Texas 77054, United States.

出版信息

ACS Chem Biol. 2020 Jun 19;15(6):1630-1641. doi: 10.1021/acschembio.0c00264. Epub 2020 Apr 30.

Abstract

Programmed death ligand 1 (PD-L1) is a critical immune checkpoint ligand whose overexpression on tumor cells provides a mechanism of escape from immune surveillance. The interaction between PD-L1 and PD-1 on T cell lymphocytes suppresses both T cell activation and effector function and is engaged by cancers to dampen antitumor immunity. Here, we used mRNA display to engineer an 18-residue linear peptide that binds to human PD-L1. This peptide, which we term SPAM (signal peptide-based affinity maturated ligand), is nonhomologous to known PD-L1 binding peptides and mAbs, with dissociation constants () of 119 and 67 nM for unglycosylated and glycosylated human PD-L1, respectively. The SPAM peptide is highly selective for human PD-L1 and shows no significant binding to either mouse PD-L1 or human PD-L2. Competition binding assays indicate that the SPAM peptide binding site overlaps with the binding site of PD-1 as well as therapeutic anti-PD-L1 antibodies. Taken together, these results suggest that the SPAM peptide specifically binds to human PD-L1 and could potentially serve as a PD-L1 affinity agent and PD-L1/PD-1 pathway modulator.

摘要

程序性死亡配体1(PD-L1)是一种关键的免疫检查点配体,其在肿瘤细胞上的过表达提供了一种逃避免疫监视的机制。PD-L1与T淋巴细胞上的PD-1之间的相互作用抑制了T细胞的活化和效应功能,癌症利用这种相互作用来削弱抗肿瘤免疫力。在此,我们利用mRNA展示技术设计了一种与人类PD-L1结合的18个氨基酸残基的线性肽。我们将这种肽命名为SPAM(基于信号肽的亲和力成熟配体),它与已知的PD-L1结合肽和单克隆抗体无同源性,对未糖基化和糖基化的人类PD-L1的解离常数(KD)分别为119 nM和67 nM。SPAM肽对人类PD-L1具有高度选择性,对小鼠PD-L1或人类PD-L2均无明显结合。竞争结合试验表明,SPAM肽的结合位点与PD-1以及治疗性抗PD-L1抗体的结合位点重叠。综上所述,这些结果表明SPAM肽能特异性结合人类PD-L1,并有可能作为一种PD-L1亲和剂和PD-L1/PD-1通路调节剂。

相似文献

引用本文的文献

4
Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display.基于 mRNA 展示技术的靶向 PD-L1 的亲和体定向进化。
ACS Chem Biol. 2022 Jun 17;17(6):1543-1555. doi: 10.1021/acschembio.2c00218. Epub 2022 May 25.
5
Directing evolution of novel ligands by mRNA display.通过 mRNA 展示定向进化新型配体。
Chem Soc Rev. 2021 Aug 21;50(16):9055-9103. doi: 10.1039/d1cs00160d. Epub 2021 Jun 24.
6
Peptides that immunoactivate the tumor microenvironment.免疫激活肿瘤微环境的肽。
Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188486. doi: 10.1016/j.bbcan.2020.188486. Epub 2020 Dec 1.
7
Expanding the Chemical Diversity of Genetically Encoded Libraries.拓展基因编码文库的化学多样性。
ACS Comb Sci. 2020 Dec 14;22(12):712-733. doi: 10.1021/acscombsci.0c00179. Epub 2020 Nov 9.

本文引用的文献

2
Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer.基于抗 PD1/PD-L1 骨干:癌症的联合免疫疗法。
Expert Opin Investig Drugs. 2019 Aug;28(8):695-708. doi: 10.1080/13543784.2019.1649657. Epub 2019 Aug 6.
7
Cemiplimab: First Global Approval.西尼莫单抗:全球首次获批。
Drugs. 2018 Nov;78(17):1841-1846. doi: 10.1007/s40265-018-1012-5.
10
Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy.肽阻断 PD-1/PD-L1 相互作用用于癌症免疫治疗。
Cancer Immunol Res. 2018 Feb;6(2):178-188. doi: 10.1158/2326-6066.CIR-17-0035. Epub 2017 Dec 7.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验